Correction to: A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications (Scientific Reports, (2024), 14, 1, (13462), 10.1038/s41598-024-64260-9)

Abstract

Correction to: Scientific Reportshttps://doi.org/10.1038/s41598-024-64260-9, published online 12 June 2024 The original version of this Article contained errors. In the Results, under the subheading ‘Qualitative analysis’, ‘Long-covid studies’, “A retrospective analysis of patients taking SSRIs at the time of infection showed a % reduction (p = 0.0004) in the relative risk of Long-covid among patients (n = 1521) receiving an SSRI with σ1R agonism (fluvoxamine, fluoxetine, escitalopram) and a 21% reduction (p = 0.005) in the relative risk of Long-covid among patients (n = 1803) taking an SSRI without σ1R agonism (citalopram, paroxetine, sertraline) compared with patients (n = 14,584) not taking an SSRI43. However, as pointed out by K. Hashimoto44 this study included citalopram as an SSRI with σ1R activity, which other studies have suggested as incorrect as it does not potentiate NGF-induced neurite outgrowth in PC-12 cells45.” now reads: “A retrospective analysis of patients taking SSRIs at the time of infection showed a 29% reduction (p = 0.0004) in the relative risk of Long-covid among patients (n = 1521) receiving an SSRI with σ1R agonism (fluvoxamine, fluoxetine, escitalopram) and a 21% reduction (p = 0.005) in the relative risk of Long-covid among patients (n = 1803) taking an SSRI without σ1R agonism (citalopram, paroxetine, sertraline) compared with patients (n = 14,584) not taking an SSRI43. As pointed out by K. Hashimoto,44 a preprint of this study included citalopram as an SSRI with σ1R activity, which other studies have suggested as incorrect as it does not potentiate NGF-induced neurite outgrowth in PC-12 cells45.” Furthermore, Reference 43 contained an error and was incorrectly given as: Sidky, H. et al. Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. medRxiv (2022). The correct reference is listed below: Sidky, H. et al. Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. Computational and Structural Biotechnology Journal24, 115–125 (2024). https://doi.org/10.1016/j.csbj.2023.12.045 The original Article has been corrected.